Brief: Immunovant Inc - Plan To Initiate A Phase 2 Trial In Graves' Disease In Early 2023 With Initial Results Expected In Second Half Of 2023
07/09/2022 11:50
Sept 7 (Reuters) - Immunovant Inc IMVT.O :
* IMMUNOVANT INC - PLAN TO INITIATE A PHASE 2 TRIAL IN
GRAVES'
DISEASE IN EARLY 2023 WITH INITIAL RESULTS EXPECTED IN SECOND
HALF OF 2023
Source text for Eikon: ID:nGNX4lYZpv
Further company coverage: IMVT.O
(Reporting by Pratik Jain)
((Pratik.Jain@thomsonreuters.com;))
Recent news on Immunovant
See all newsU.S. STOCKS ON THE MOVE-Tesla, Blue Owl, Ford
Immunovant falls as drug for thyroid eye disease fails late-stage trials
Immunovant falls as eye disease therapy fails in late-stage studies
Immunovant Q3 net loss smaller than expected
Brief: Immunovant Q3 Net Income USD -110.635 Million Vs. IBES Estimate USD -125.1 Million